Amirhosein Maharati
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Amirhosein Maharati has a total of 27 co-authors. Here are the top co-authors by number of shared publications:
Abbas Abdollahi
Mashhad University of Medical Sciences Ghaem Hospital
1 shared publicationAbolghasem Allahyari
Department of Hematology-Oncology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
1 shared publicationAlireza Zangooie
Student Research Committee, Birjand University of Medical Sciences, Birjand, Iran
1 shared publication- Amir Avan
Medical Genetics Research Center, Mashhad University of Medical Sciences, Mashhad, Iran
1 shared publication Amir Masoud Jafari-Nozad
Student Research Committee, Birjand University of Medical Sciences, Birjand, Iran
1 shared publication- Amir Sadra Zangouei
Student Research Committee, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
1 shared publication
Latest Publications
- Open Access
- 21 September 2026
- Published by Springer Nature in Research Square
Glutamine—fructose-6-phosphate transaminase 2: A Key Biomarker and Regulator of Chemotherapy Response in Colorectal Cancer
Introduction: Colorectal cancer (CRC) ranks among the world’s most prevalent and lethal malignancies, with an estimated 1.9 million new cases and 904 000 deaths reported in 2022. The efficacy of 5-fluorouracil and oxaliplatin resistance is limited in these patients caused by altered metabolism and tumor microenvironment (TME) interactions. Cancer-associated fibroblasts (CAFs) within the TME induce chemoresistance via chemokine-mediated signaling and extracellular matrix remodeling under hypoxia. We aimed to identify key mediators of CAF-tumor crosstalk in CRC chemoresistance, focusing on GFPT2 as a candidate regulator. Materials and methods We analyzed bulk RNA-seq data from oxaliplatin- (GSE119603) and 5-FU-resistant (GSE196900), a cohort of 110 post-treatment CRC patients (GSE107422), and 398 TCGA-COAD tumors. Differential expression (|Log₂FC|>2, P < 0.05) was identified via DESeq2, and machine learning methods created prognostic chemoresistance-associated signature. We utilized two scRNA-seq datasets (GSE144735, GSE132465) to investigate the CAF-tumor interaction. We found the molecular mechanism of GFPT2-mediated CAF-tumor interaction in CRC cells. For experimental validation, total RNA from 64 paired CRC and normal tissues (2021–2023) was extracted and GFPT2 levels quantified by real-time RT-PCR. Association between all clinicopathological features and GFPT2 expression was assessed in our cohort. Results Differential expression analysis and LASSO regression yielded 17 5-FU/oxaliplatin-associated genes with robust predictive performance (AUC = 0.873). Subsequent Cox-LASSO modeling identified eight genes, including GFPT2, which defined a high-risk signature that stratified patients by survival. High-risk tumors exhibited increased TMB and immune checkpoint expression. Single-cell profiling localized GFPT2 to cancer-associated fibroblasts (CAFs). Co-regulatory network and enrichment analyses linked GFPT2-correlated genes to hypoxia pathways. Validation in CAF bulk RNA-seq confirmed strong GFPT2–hypoxia pathway association (r = 0.92, P < 0001). Moreover, cell–cell communication analysis highlighted GFPT2-dependent CAF ligands (e.g., TIMP1, SERPINE1) interacting with tumor receptors. RT-qPCR in 60 CRC tissues showed GFPT2 upregulation in CRC tissues compared to normal tissues. Its expression level was correlated with diabetes, nodal involvement, and larger tumor size (P < 0.05). Conclusion Elevated GFPT2 expression was observed in our CRC patients and was linked to larger tumor size and diabetes. Furthermore, GFPT-2 was a predictive and prognostic marker in large CRC cohorts. Mechanistically, hypoxic CAFs upregulate GFPT2 to enhance N-/O-glycosylation capacity, promoting secretion of pro-survival ligands SERPINE1 and TIMP1. These ligands bind to the LRP1 and CD63 receptors on tumor cells, activating the PI3K/AKT cascade, thereby establishing a paracrine signaling axis that suppresses 5-FU/oxaliplatin-induced apoptosis. Therefore, GFPT2 may serve as a biomarker for chemotherapy response in CRC patients with diabetes.
- 21 September 2026
- Published by Springer Nature in Research Square
Open AccessGlutamine—fructose-6-phosphate transaminase 2: A Key Biomarker and Regulator of Chemotherapy Response in Colorectal Cancer
Introduction: Colorectal cancer (CRC) ranks among the world’s most prevalent and lethal malignancies, with an estimated 1.9 million new cases and 904 000 deaths reported in 2022. The efficacy of 5-fluorouracil and oxaliplatin resistance is limited in these patients caused by altered metabolism and tumor microenvironment (TME) interactions. Cancer-associated fibroblasts (CAFs) within the TME induce chemoresistance via chemokine-mediated signaling and extracellular matrix remodeling under hypoxia. We aimed to identify key mediators of CAF-tumor crosstalk in CRC chemoresistance, focusing on GFPT2 as a candidate regulator. Materials and methods We analyzed bulk RNA-seq data from oxaliplatin- (GSE119603) and 5-FU-resistant (GSE196900), a cohort of 110 post-treatment CRC patients (GSE107422), and 398 TCGA-COAD tumors. Differential expression (|Log₂FC|>2, P < 0.05) was identified via DESeq2, and machine learning methods created prognostic chemoresistance-associated signature. We utilized two scRNA-seq datasets (GSE144735, GSE132465) to investigate the CAF-tumor interaction. We found the molecular mechanism of GFPT2-mediated CAF-tumor interaction in CRC cells. For experimental validation, total RNA from 64 paired CRC and normal tissues (2021–2023) was extracted and GFPT2 levels quantified by real-time RT-PCR. Association between all clinicopathological features and GFPT2 expression was assessed in our cohort. Results Differential expression analysis and LASSO regression yielded 17 5-FU/oxaliplatin-associated genes with robust predictive performance (AUC = 0.873). Subsequent Cox-LASSO modeling identified eight genes, including GFPT2, which defined a high-risk signature that stratified patients by survival. High-risk tumors exhibited increased TMB and immune checkpoint expression. Single-cell profiling localized GFPT2 to cancer-associated fibroblasts (CAFs). Co-regulatory network and enrichment analyses linked GFPT2-correlated genes to hypoxia pathways. Validation in CAF bulk RNA-seq confirmed strong GFPT2–hypoxia pathway association (r = 0.92, P < 0001). Moreover, cell–cell communication analysis highlighted GFPT2-dependent CAF ligands (e.g., TIMP1, SERPINE1) interacting with tumor receptors. RT-qPCR in 60 CRC tissues showed GFPT2 upregulation in CRC tissues compared to normal tissues. Its expression level was correlated with diabetes, nodal involvement, and larger tumor size (P < 0.05). Conclusion Elevated GFPT2 expression was observed in our CRC patients and was linked to larger tumor size and diabetes. Furthermore, GFPT-2 was a predictive and prognostic marker in large CRC cohorts. Mechanistically, hypoxic CAFs upregulate GFPT2 to enhance N-/O-glycosylation capacity, promoting secretion of pro-survival ligands SERPINE1 and TIMP1. These ligands bind to the LRP1 and CD63 receptors on tumor cells, activating the PI3K/AKT cascade, thereby establishing a paracrine signaling axis that suppresses 5-FU/oxaliplatin-induced apoptosis. Therefore, GFPT2 may serve as a biomarker for chemotherapy response in CRC patients with diabetes.
- Open Access
- 31 October 2025
- Published by Springer Nature in Cell Biology and Toxicology
- Vol. 41 (1) , 1-34
HypoxamiRs in pancreatic cancer: master regulators of the hypoxic tumor microenvironment
Pancreatic cancer (PC) is characterized by aggressive progression, chemoresistance, and immune evasion, largely driven by its hypoxic tumor microenvironment (TME). The extensive desmoplastic reaction in PC, characterized by dense stromal fibrosis, exacerbates hypoxia by impairing blood flow, creating a hostile environment that limits therapeutic efficacy. Hypoxia-induced microRNAs (HypoxamiRs) have emerged as critical regulators of these processes, modulating cellular pathways that promote tumor survival and therapy resistance. HypoxamiRs exert their effects by interacting with hypoxia-inducible factors, including HIF-1α and HIF-2α. Beyond their direct impact on tumor cells, HypoxamiRs modulate the behavior of immune and stromal cells within the hypoxic TME. Key contributors to hypoxia, such as cancer-associated fibroblasts, pancreatic stellate cells, macrophages, and natural killer (NK) cells, facilitate HypoxamiR transfer via exosomes. This review explores the multifaceted roles of HypoxamiRs in key processes such as immune modulation, chemoresistance, epithelial-mesenchymal transition (EMT), autophagy, angiogenesis, and apoptosis in pancreatic cancer. We also highlight the complex interplay between HypoxamiRs and other non-coding RNAs (ncRNAs) in regulating hypoxia-driven pathways. Investigating these complex interactions provides critical insights for developing novel therapeutic strategies to overcome chemoresistance and immune evasion in pancreatic cancer.
- 31 October 2025
- Published by Springer Nature in Cell Biology and Toxicology
- Vol. 41 (1) , 1-34
Open AccessHypoxamiRs in pancreatic cancer: master regulators of the hypoxic tumor microenvironment
Pancreatic cancer (PC) is characterized by aggressive progression, chemoresistance, and immune evasion, largely driven by its hypoxic tumor microenvironment (TME). The extensive desmoplastic reaction in PC, characterized by dense stromal fibrosis, exacerbates hypoxia by impairing blood flow, creating a hostile environment that limits therapeutic efficacy. Hypoxia-induced microRNAs (HypoxamiRs) have emerged as critical regulators of these processes, modulating cellular pathways that promote tumor survival and therapy resistance. HypoxamiRs exert their effects by interacting with hypoxia-inducible factors, including HIF-1α and HIF-2α. Beyond their direct impact on tumor cells, HypoxamiRs modulate the behavior of immune and stromal cells within the hypoxic TME. Key contributors to hypoxia, such as cancer-associated fibroblasts, pancreatic stellate cells, macrophages, and natural killer (NK) cells, facilitate HypoxamiR transfer via exosomes. This review explores the multifaceted roles of HypoxamiRs in key processes such as immune modulation, chemoresistance, epithelial-mesenchymal transition (EMT), autophagy, angiogenesis, and apoptosis in pancreatic cancer. We also highlight the complex interplay between HypoxamiRs and other non-coding RNAs (ncRNAs) in regulating hypoxia-driven pathways. Investigating these complex interactions provides critical insights for developing novel therapeutic strategies to overcome chemoresistance and immune evasion in pancreatic cancer.
- Open Access
- 5 February 2023
- Published by Springer Nature in Journal of Medical Case Reports
- Vol. 17 (1) , 1-6
Prostate cancer, chronic myelogenous leukemia and multiple myeloma in a single patient: a case report and review of the literature
Background: Synchronous or metachronous multiple primary malignancies (MPMs) are a known phenomenon. These occurrences may be spontaneous or related to environmental risk factors or genetic predisposition. Chronic myelogenous leukemia (CML) and Multiple myeloma (MM) are two uncommon hematologic malignancies, arises from two different cell lineage. The coexistence of CML and MM that is a rare phenomenon, with only 29 cases reported in the literature. To the best of our, this combination of triple primary cancers has not been reported in a single patient. Case presentation: Herein, we reported a case of an 85-year-old Iranian male with three confirmed primary malignant neoplasms. The patient presented with synchronous prostate cancer and CML, in august 2016. He received imatinib and nilotinib for CML and hormonal therapy for prostate cancer. He remained in good control at further follow-ups for about 5 years. In the follow-up period and after 61 months treatment with tyrosine kinase inhibitors (TKIs), CML was undetectable in molecular tests, but the presence of serum M-protein, abnormal plasma cells in the bone marrow, and CRAB criteria was compatible with MM. Conclusion: We must evaluate the possibility of multiple primary cancers during cancer treatment and follow-up and it may be worthwhile to monitor serum electrophoresis and protein levels in TKIs-treated patients.
- 5 February 2023
- Published by Springer Nature in Journal of Medical Case Reports
- Vol. 17 (1) , 1-6
Open AccessProstate cancer, chronic myelogenous leukemia and multiple myeloma in a single patient: a case report and review of the literature
Background: Synchronous or metachronous multiple primary malignancies (MPMs) are a known phenomenon. These occurrences may be spontaneous or related to environmental risk factors or genetic predisposition. Chronic myelogenous leukemia (CML) and Multiple myeloma (MM) are two uncommon hematologic malignancies, arises from two different cell lineage. The coexistence of CML and MM that is a rare phenomenon, with only 29 cases reported in the literature. To the best of our, this combination of triple primary cancers has not been reported in a single patient. Case presentation: Herein, we reported a case of an 85-year-old Iranian male with three confirmed primary malignant neoplasms. The patient presented with synchronous prostate cancer and CML, in august 2016. He received imatinib and nilotinib for CML and hormonal therapy for prostate cancer. He remained in good control at further follow-ups for about 5 years. In the follow-up period and after 61 months treatment with tyrosine kinase inhibitors (TKIs), CML was undetectable in molecular tests, but the presence of serum M-protein, abnormal plasma cells in the bone marrow, and CRAB criteria was compatible with MM. Conclusion: We must evaluate the possibility of multiple primary cancers during cancer treatment and follow-up and it may be worthwhile to monitor serum electrophoresis and protein levels in TKIs-treated patients.
- Open Access
- 9 March 2022
- Published by Springer Nature in Cell Communication and Signaling
- Vol. 20 (1) , 1-16
MicroRNAs as the critical regulators of tyrosine kinase inhibitors resistance in lung tumor cells
Lung cancer is the second most common and the leading cause of cancer related deaths globally. Tyrosine Kinase Inhibitors (TKIs) are among the common therapeutic strategies in lung cancer patients, however the treatment process fails in a wide range of patients due to TKIs resistance. Given that the use of anti-cancer drugs can always have side effects on normal tissues, predicting the TKI responses can provide an efficient therapeutic strategy. Therefore, it is required to clarify the molecular mechanisms of TKIs resistance in lung cancer patients. MicroRNAs (miRNAs) are involved in regulation of various pathophysiological cellular processes. In the present review, we discussed the miRNAs that have been associated with TKIs responses in lung cancer. MiRNAs mainly exert their role on TKIs response through regulation of Tyrosine Kinase Receptors (TKRs) and down-stream signaling pathways. This review paves the way for introducing a panel of miRNAs for the prediction of TKIs responses in lung cancer patients.
- 9 March 2022
- Published by Springer Nature in Cell Communication and Signaling
- Vol. 20 (1) , 1-16
Open AccessMicroRNAs as the critical regulators of tyrosine kinase inhibitors resistance in lung tumor cells
Lung cancer is the second most common and the leading cause of cancer related deaths globally. Tyrosine Kinase Inhibitors (TKIs) are among the common therapeutic strategies in lung cancer patients, however the treatment process fails in a wide range of patients due to TKIs resistance. Given that the use of anti-cancer drugs can always have side effects on normal tissues, predicting the TKI responses can provide an efficient therapeutic strategy. Therefore, it is required to clarify the molecular mechanisms of TKIs resistance in lung cancer patients. MicroRNAs (miRNAs) are involved in regulation of various pathophysiological cellular processes. In the present review, we discussed the miRNAs that have been associated with TKIs responses in lung cancer. MiRNAs mainly exert their role on TKIs response through regulation of Tyrosine Kinase Receptors (TKRs) and down-stream signaling pathways. This review paves the way for introducing a panel of miRNAs for the prediction of TKIs responses in lung cancer patients.